A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A study for patients with soft tissue sarcoma using study drug olaratumab
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ8127
U.S. Govt. ID: NCT02659020
Contact: Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out how safe study drug olaratumab given with gemcitabine and docetaxel is for patients and whether olaratumab given with gemcitabine and docetaxel can help patients with advanced or metastatic soft tissue sarcoma (STS).
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Have you been diagnosed with Soft Tissue Sarcoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Ryan Shelton
rs3323@cumc.columbia.edu
212-304-5485
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE